Loading
A phase 1/2 trial of serplulimab in colorectal cancer, run by Shanghai Henlius Biotech, not yet recruiting.
A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer is a phase 1/2, randomised interventional study registered as NCT07358585 by Shanghai Henlius Biotech, with a registry enrolment figure of 126 participants, started 2026-01-31 and due to reach its primary completion in 2027-07-28. Interventions recorded: HLX43 dose 1 + HLX07; HLX43 dose 2 + HLX07; HLX43 dose 3 + Serplulimab; HLX43 dose 4 + Serplulimab. Conditions listed: Colon Cancer Adenocarcinoma. Primary outcome: ORR; PFS. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed advanced or metastatic colorectal adenocarcinoma; and locally tested and confirmed as a RAS/BRAF wild-type tumor (only for Part 1 );". Sites: China. No results are recorded here; the registry entry is the source.
Shares Serplulimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Shanghai Henlius Biotech, Serplulimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Serplulimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.